Medicare would cover blood tests for early Alzheimer's detection
In markupH.R. 6130Latest action
Sponsor: Vern Buchanan · Representative · FL
AIDecoded by AI · checked against the recordRead the official text
Official title: ASAP Act
119th Congress
Topics: Health care
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
Starting in 2028, Medicare would be required to cover FDA-approved blood tests that detect Alzheimer's and related dementias early.
45-second read · 4 questions answered below
What does this do?
This bill would require Medicare to cover blood-based tests that can detect Alzheimer's disease and related dementias before or in the early stages of symptoms, starting January 1, 2028. To qualify, a test must be FDA-approved or cleared and must analyze blood or other biological samples, including tests that look at genes, proteins, cell-free nucleic acids, or similar markers. The agency overseeing Medicare would decide which specific tests qualify, as long as results are comparable to the core blood-based tests described in the bill.
Who does it affect?
Medicare enrollees would be affected — generally people 65 and older, as well as certain people with disabilities.
Why does it matter?
Requiring coverage could remove out-of-pocket costs for these early detection tests for Medicare enrollees. People who could not otherwise afford these screenings may gain access to them.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedNov 19, 2025
- House committeeYou are here · Sep 16, 2026
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0.